Skip to content

PROPEL Study: An Investigational New Treatment for Myasthenia Gravis

Search Clinical Trials

Trial Objectives


Generalized myasthenia gravis, or gMG, is a condition where the muscles under voluntary control experience weakness and rapid fatigue, and is caused by the breakdown in normal communication between nerves and muscles. Researchers in the PROPEL study are evaluating an investigational treatment to see if it may help muscles get the signals they need to work properly.

In this study, participants will be randomly assigned to receive either the study medication (called IMVT-1402) or a placebo (an injection with no active medication) for the first 12 weeks.

After the first 12 weeks, every participant will be randomly assigned to receive one of two different doses of the active study treatment, IMVT-1402.

Starting after Week 2, participants may be given study medication at clinic visits to take home and self-inject. Injections can also be given at the study site by trained staff, if preferred.  Participants will also have physical exams and lab tests, and will complete questionnaires about their symptoms and quality of life during clinic visits. These visits help researchers monitor participants' health and check for any side effects or reactions to the study medication.
 

Who Can Participate


Adults 18-80 years old who have been diagnosed with mild to severe generalized myasthenia gravis (gMG)
 

Age: 18-80 Gender: Any

Estimated Time Commitment


At least 28 visits over approximately a year and 8 months

Payment & Reimbursement


Payment: Provided

Travel Reimbursement: Available

Trial Contact


For more information, contact:

Shane Hopkins
303.270.2622

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Immunovant Sciences GmbH

Principal Investigators

Jinny Tavee

Jinny Tavee, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required